Over the last few years, our group and others have focused on the cardiovascular actions of glucagon-like peptide-1 (GLP-1), whose established metabolic effects have been clinically exploited for glycemic control in type 2 diabetes [14, 41]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.